MedTrace Logo

Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis

NCT04771988 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2021-02-25

No results posted yet for this study

Summary

In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of such patients are not only able to achieve stability of the disease, but also to obtain a complete radiological response (CR). The possibility of achieving a CR might allow these patients to be listed for liver transplantation (LT), in order to cure not only the cancer but also the underlying cirrhosis that generated it.

Conditions

Interventions

RADIATION

yttrium-90 radioembolization

selective/superselective treatment using resin microspheres labeled with Yttrium-90

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • rita golfieri, MD · Azienda Ospedaliero-Universitaria di Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-08
Primary Completion
2017-05-08
Completion
2020-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04771988 on ClinicalTrials.gov